Non-human primate preclinical model revealed the feasibility and short-term safety of iPSC-derived innate-like T cells in autologous transplantation
These findings establish a unique immunocompetent primate model for assessing the safety and <i>in vivo</i> behavior of iPSC-T cells. This platform enables more physiologically relevant preclinical evaluation and supports the development of iPSC-derived T-cell immunotherapies for cancer and autoimmune diseases.
Authors
- Hiromi Sakawaki
- Eri Imai (ORCID: https://orcid.org/0000-0002-2376-077X)
- Kahoru Taya
- Shoichi Iriguchi
- Shuichi Kitayama
- Hiroshi Ishii (ORCID: https://orcid.org/0000-0002-3295-4867)
- T. Miura
- Y. Miyake (ORCID: https://orcid.org/0000-0001-6250-0260)
- Tetsuro Matano
- Shin Kaneko
- Ai Kawana-Tachikawa
Institutions
- Kaneka (United States) (US)
- Tokyo University of Science (JP)
- Kyoto University (JP)
- National Institute of Infectious Diseases (JP)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2026-01-23
- DOI
- https://doi.org/10.3389/fimmu.2025.1653275
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Institute of Advanced Industrial Science and Technology
- Ministry of Education, Culture, Sports, Science and Technology
- Japan Society for the Promotion of Science
- Primate Research Institute, Kyoto University